Partners

Mundipharma

Cidara and Mundipharma have entered into a strategic partnership to develop and commercialize rezafungin for the treatment and prevention of invasive fungal disease in all markets outside of the U.S. and Japan, which will be retained by Cidara.

Mundipharma is a global network of privately-owned independent associated companies whose purpose is to move medicine forward. Mundipharma strives for innovation and commercial excellence to create value for patients, payers, and the wider healthcare systems across important therapeutic areas.

GET IMPORTANT NEWS AND UPDATES BY EMAIL